Xcelom Limited (Global)
Next Generation Sequencing
Towards the postgenomic era
Affordable Clinical Sequencing to Routine Practice
Sequencing technology has advanced significantly since the late 1970s. Since the commercialization of Sanger sequencing in 1987, sequencing has revolutionized the field of molecular biology. The arrival of Illumina’s Next-Generation Sequencing (NGS) accelerated this progress by significantly lowering costs and increasing throughput. Today, these advancements allow clinicians to access high-depth sequencing for individual patients at a fraction of the historical cost, facilitating more precise diagnoses and management.
While the cost of NGS sequencing runs has dropped dramiatically, implementing NGS for clinical use requires far more than just the runs. For service laboratory, they also requires a reliable, efficient workflow and deep experience to standardize processes and achieving the test performance reliability and reproducibility.
We are the Pioneers and Expert in Clinical NGS Services
Berry Genomics, our parent company, is a pioneer in clinical NGS services and technology transfer. Since launching China's first NIPT in 2010, Berry Genomics has expanded to serve over 2,000 hospitals, with more than 100 medical centers adopting the technology to build their own labs. Offering comprehensive testing from preconception to adulthood, Xcelom and Berry Genomics are dedicated to developing and commercializing the latest advanced technologies.
Extensive Portfolio
PGT
Carrier Screening
Prenatal Testing
Newborn Screening
Disease Diagnosis
Proven Scale & Experience
With a testing volume:
> 5 Million NIPT
> 100,000 CNV-seq
> 20,000 WES
Proprietary Innovation
Exclusive, self-developed library preparation and bioinformatics pipelines
Certified Excellence
Fully accredited by CAP and ISO standards
Custom Solutions
Tailored panels and tech transfer to deploy solutions in your lab
Standardized NGS Panel
BambniTest™ NIPT utilizes our patented PCR-free rapid library preparation method EZ-PALO™, along with our ultra-fast proprietary bioinformatics algorithm RUPA™. This service was validated in over 1,000,000 cases and has been adopted by over 100 clinical institutions. With its proven record, BambniTest NIPT™ stands out as a trusted choice for accurate and efficient prenatal screening.
BambniTest™ NIPT-SGD is an advanced NIPT that targets specific SNV/InDels in 66 genes associated with 66 autosomal dominant or X-linked single gene disorders. This service enables non-invasive early screening for severe, high-penetrance disorders that primarily caused by de novo mutations with a low miss rate, facilitating early diagnosis and intervention.
Xromate™ CNV-seq utilizes patented EZ-GALO rapid PCR-free library and CNVisi Integrated analysis and reporting system to analyze CNVs for prenatal diagnostics, miscarriage analysis, and investigating genetic causes in patients. Since 2014, Xromate has processed over 300,000 cases, with dozens of institutions implementing it in their laboratories.
ChroSure™ PGT includes comprehensive PGT solutions for aneuploidy (PGT-A), single gene disorders (PGT-M and smrtPGT-M), and structural rearrangements (PGT-SR and smrtPGT-SR) through our innovative technologies. Our PGT-A service is designed for localized implementation with a patented integrated workflow. Additionally, smrtPGT-M and smrtPGT-SR utilize single molecule real-time (SMRT) sequencing technology to address the limitations of current PGT-M and PGT-SR methods, providing solutions for complex cases even with limited sample availability.
SecureCari™ ECS is designed to screen for hundreds of autosomal and X-linked recessive single gene disorders with our Clinical Sequencing Platform (CES). Utilizing our PCR-free eWES library preparation can reduce the biases and base mismatches associated with amplification significantly. This approach enhances the uniformity of coverage and increases the sensitivity andspecificity of detection, optimizing test performance.
NBSure™ Newborn Genetic Screening screens for hundreds of singe gene disorders with our Clinical Sequencing Platform (CES). It provides an expanded neonatal care solution with a comprehensive scope of service. Genetic-based first-tier screening can facilitate early diagnosis and management, improving patient outcomes and reducing the clinical burden associated with inconclusive biochemical findings.
OeXome™ WES provides a highly accurate and in-depth solution for physicians and researchers to investigate genetic factors that may be relevant to a patient's phenotype, fetal abnormalities, or provide additional insights. With our selfdeveloped experimental and bioinformatics pipeline, combined with the expertise of our team, we deliver high-quality, reliable results to support your work with confidence.
WGS targets and analyzes DNA sequences across the entire genome. By covering both coding and non-coding regions, WGS detects a significantly wider range of variants than our NGS panels. This is crucial for identifying pathogenic variants located in deep intronic or non-coding regions often not covered by other tests. It helps to achieve greater diagnostic timeliness and cost-effectiveness by consolidating testing process.
Advanced Customization
Beyond our standard offerings, we specialize in the development of tailored NGS solutions. Our team is prepared to partner with you on the co-development of custom clinical panels and project-specific initiatives, leveraging our full R&D and manufacturing capabilities to support your strategic goals.